Lactulose
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Lactulose: From Unrecorded Original Indication to Acute Urate Nephropathy
One-Sentence Summary
Lactulose (DrugBank DB00581) has no recorded original indication or Taiwan market license in this evidence pack — it is currently 未上市 (not marketed) in Taiwan with zero approved licenses. The TxGNN model’s top-ranked prediction is Acute Urate Nephropathy, but this candidate has zero clinical trials and zero publications supporting it — it is a pure model-score prediction with no mechanistic or clinical backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented — evidence pack lists no original indications and no Taiwan license record |
| Predicted New Indication | Acute Urate Nephropathy |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for lactulose in this evidence pack (flagged as a High-severity data gap, DG002), and no original indication is on record.
For the top-ranked prediction specifically, the evidence pack’s own mechanistic assessment concludes there is no known link: lactulose does not affect urate metabolism or renal tubular urate crystal deposition. There is no pharmacological rationale connecting lactulose’s known activity (as a non-absorbable disaccharide acting osmotically/on colonic flora) to acute urate nephropathy.
Combined with the complete absence of clinical trials or literature for this disease pairing, this prediction should be treated as knowledge-graph noise rather than a credible repurposing hypothesis at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No licensed products found in the Taiwan regulatory database — lactulose is currently not marketed (0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (acute urate nephropathy) has no clinical trials, no literature, and no plausible mechanistic link — it is a pure model-score artifact. Combined with a Blocking-severity data gap on TFDA labeling/warnings (DG001) and missing MOA data (DG002), there is currently no basis to advance this candidate past screening.
To proceed, the following is needed:
- TFDA label/warnings and contraindications (blocking gap, required before any safety pre-assessment)
- Confirmed mechanism of action data from DrugBank
- Confirmed original indication and licensing history for lactulose
- Independent mechanistic or preclinical rationale connecting lactulose to acute urate nephropathy before further investment
Note: This evidence pack also contains a considerably stronger candidate further down the ranked list — obstructive jaundice (rank 3, score 99.53%, Evidence Level L3) — supported by 1 completed Phase 4 trial and 20 publications, including a multicentre RCT (PMID 2032107) on lactulose preventing postoperative renal dysfunction in obstructive jaundice. If a repurposing candidate is desired from this evidence pack, that pairing warrants a separate, dedicated evaluation report rather than the top TxGNN score alone.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.